SequelSEC

FRACTYL HEALTH, INC. GUTS

Surgical & Medical Instruments & Apparatus · CIK 0001572616 · Fiscal year ends 1231

Revenue
$93.00K
Fiscal year ended 2024-12-31
Operating income
-$93.53M
Fiscal year ended 2024-12-31
Free cash flow
-$67.29M
Fiscal year ended 2024-12-31

Valuation, from the filing

Public float$49.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.31Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity5.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth-100.0%0th
Current ratio4.78x73th

FRACTYL HEALTH, INC. (GUTS) reported revenue of $93.00K and net income of -$68.69M for the fiscal year ended 2024-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from FRACTYL HEALTH, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

FRACTYL HEALTH, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Revenue$93.00K
Cost of revenue$50.00K
Gross profit$43.00K
Operating income-$93.53M
Net income-$68.69M
Research & development$70.47M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$23.10M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

FRACTYL HEALTH, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Cash & equivalents$67.46M
Total assets$108.08M
Current assets$71.76M
Total liabilities$79.65M
Current liabilities$19.78M
Total equity incl. NCI$28.42M
Temporary (mezzanine) equity$0
Inventory$73.00K
Accounts receivable$0
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$3.24M

Cash flow

FRACTYL HEALTH, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Operating cash flow-$65.52M
Capital expenditures$1.76M
Investing cash flow-$1.76M
Financing cash flow$101.23M
Net change in cash$33.94M
Stock-based compensation$14.43M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

FRACTYL HEALTH, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Free cash flow-$67.29M
Gross margin46.2%
Operating margin-100571.0%
FCF margin-72350.5%
SBC / revenue15511.8%
Current ratio3.63x
Revenue YoY growth-22.5%
Net margin-73864.5%
R&D / revenue75775.3%
CapEx / revenue1897.8%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GUTS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-24View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.